FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Buckheit

Research Profile

Living Beings

HIV-1
HIV-2

Chemicals & Drugs

Anatomy

Physiology

Concepts & Ideas

Structure-Activity Relationship

Disorders

Procedures

Microbial Sensitivity Tests

Genes & Molecular Sequences

Molecular Structure

Co-author Network

Publications

TOP 3
Robert W Buckheit; Maria Salgado; Robert F Silciano; Joel N Blankson
Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors.
Charlene S Dezzutti; Garry Gwozdz; Alamelu Mahalingam; Cory Shetler; Shweta R Ugaonkar; Karen W Buckheit; Robert W Buckheit
Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.
Hitesh K Agarwal; Karen W Buckheit; Robert W Buckheit; Keykavous Parang
Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Buckheit (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Robert W Buckheit; Maria Salgado; Robert F Silciano; Joel N Blankson
Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors.
Journal of virology 2012;86(24):13679-88.
2012: Charlene S Dezzutti; Garry Gwozdz; Alamelu Mahalingam; Cory Shetler; Shweta R Ugaonkar; Karen W Buckheit; Robert W Buckheit
Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.
Antiviral research 2012;96(2):221-5.
2012: Hitesh K Agarwal; Karen W Buckheit; Robert W Buckheit; Keykavous Parang
Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.
Bioorganic & medicinal chemistry letters 2012;22(17):5451-4.
2012: Anthony S Ham; Lisa Cencia Rohan; Karen W Buckheit; Lu Yang; Ashlee Boczar; Robert W Buckheit
Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection.
Pharmaceutical research 2012;29(7):1897-907.
2012: Anthony S Ham; Patrick F Kiser; Howard Lakougna; Umadevi Nagaraja; Lianjun Shi; Shweta R Ugaonkar; Karen Watson Buckheit; Laurie Goldman; Garry Gwozdz; Robert W Buckheit
Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
Journal of pharmaceutical sciences 2012;101(4):1423-35.
2012: Karen W Buckheit; Robert W Buckheit
Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1.
Molecular biology international 2012;2012():781305.
2012: Tracy L Hartman; Robert W Buckheit
The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets.
Molecular biology international 2012;2012():401965.
2012: Robert W Buckheit; Oluwaseun Falade-Nwulia; Joel E Gallant; Sarah Huculak; Karen A O'Connell; Maria Salgado; Robert Siliciano; Thomas M Williams; Tracy G Allen; Angela Alme; Joel N Blankson
Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs.
Nature communications 2012;3():716.
2012: Robert W Buckheit; Karen W Buckheit
An algorithm for the preclinical development of anti-HIV topical microbicides.
Current HIV research 2012;10(1):97-104.
2011: Tracy L Hartman; Lu Yang; Robert W Buckheit
Antiviral interactions of combinations of highly potent 2,4(1H,3H)-pyrimidinedione congeners and other anti-HIV agents.
Antiviral research 2011;92(3):505-8.
2011: Karen Watson Buckheit; Lu Yang; Robert W Buckheit
Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides.
Antimicrobial agents and chemotherapy 2011;55(11):5243-54.
2011: Meredith R Clark; Hyder A Aliyar; Chang-won Lee; Julie I Jay; Kavita M Gupta; Karen M Watson; Russell J Stewart; Robert W Buckheit; Patrick F Kiser
Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles.
International journal of pharmaceutics 2011;413(1-2):10-18.
2011: Alamelu Mahalingam; Adam P Simmons; Shweta R Ugaonkar; Karen M Watson; Charlene S Dezzutti; Lisa C Rohan; Robert W Buckheit; Patrick F Kiser
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1.
Antimicrobial agents and chemotherapy 2011;55(4):1650-60.
2010: Mikhail S Novikov; Robert W Buckheit; Kartik Temburnikar; Anastasia L Khandazhinskaya; Alexander V Ivanov; Katherine L Seley-Radtke
1-Benzyl derivatives of 5-(arylamino)uracils as anti-HIV-1 and anti-EBV agents.
Bioorganic & medicinal chemistry 2010;18(23):8310-4.
2010: E Randall Lanier; Roger G Ptak; Bernhard M Lampert; Laurie Keilholz; Tracy Hartman; Robert W Buckheit; Marie K Mankowski; Mark C Osterling; Merrick R Almond; George R Painter
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Antimicrobial agents and chemotherapy 2010;54(7):2901-9.
2010: Roger G Ptak; Brian G Gentry; Tracy L Hartman; Karen M Watson; M Clayton Osterling; Robert W Buckheit; Leroy B Townsend; John C Drach
Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.
Antimicrobial agents and chemotherapy 2010;54(4):1512-9.
2010: Guangshun Wang; Karen M Watson; Alan Peterkofsky; Robert W Buckheit
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.
Antimicrobial agents and chemotherapy 2010;54(3):1343-6.
2010: Susan M Baker; Robert W Buckheit; Matthias M Falk
Green-to-red photoconvertible fluorescent proteins: tracking cell and protein dynamics on standard wide-field mercury arc-based microscopes.
BMC cell biology 2010;11():15.
2010: John B Bremner; Paul A Keller; Stephen G Pyne; Timothy P Boyle; Zinka Brkic; Dorothy M David; Adel Garas; Jody Morgan; Mark Robertson; Kittiya Somphol; Michael H Miller; Adam S Howe; Paul Ambrose; Sujata Bhavnani; Thomas R Fritsche; Douglas J Biedenbach; Ronald N Jones; Robert W Buckheit; Karen M Watson; Dean Baylis; Jonathan A Coates; John Deadman; Dharshini Jeevarajah; Andrea McCracken; David I Rhodes
Binaphthyl-based dicationic peptoids with therapeutic potential.
Angewandte Chemie (International ed. in English) 2010;49(3):537-40.
2010: Robert W Buckheit; Karen M Watson; Kathleen M Morrow; Anthony S Ham
Development of topical microbicides to prevent the sexual transmission of HIV.
Antiviral research 2010;85(1):142-58.
2009: Deyun Wang; Jaclyn Iera; Heather Baker; Priscilla Hogan; Roger Ptak; Lu Yang; Tracy Hartman; Robert W Buckheit; Alexandre Desjardins; Ao Yang; Pascale Legault; Venkat Yedavalli; Kuan-Teh Jeang; Daniel H Appella
Multivalent binding oligomers inhibit HIV Tat-TAR interaction critical for viral replication.
Bioorganic & medicinal chemistry letters 2009;19(24):6893-7.
2009: Matthew D Cullen; William C Ho; Joseph D Bauman; Kalyan Das; Eddy Arnold; Tracy L Hartman; Karen M Watson; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.
Journal of medicinal chemistry 2009;52(20):6467-73.
2009: Matthias M Falk; Susan M Baker; Anna M Gumpert; Dominique Segretain; Robert W Buckheit
Gap junction turnover is achieved by the internalization of small endocytic double-membrane vesicles.
Molecular biology of the cell 2009;20(14):3342-52.
2009: Bo-Liang Deng; Yujie Zhao; Tracy L Hartman; Karen Watson; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
European journal of medicinal chemistry 2009;44(3):1210-4.
2008: Warner Greene; zeger debyser; Yasuhiro Ikeda; Eric O Freed; Edward Stephens; Wes Yonemoto; Robert W Buckheit; José A Esté; Tomas Cihlar
Novel targets for HIV therapy.
Antiviral research 2008;80(3):251-65.
2008: Guangshun Wang; Karen M Watson; Robert W Buckheit
Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.
Antimicrobial agents and chemotherapy 2008;52(9):3438-40.
2008: Karen M Watson; Christa E Buckheit; Robert W Buckheit
Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay.
Antimicrobial agents and chemotherapy 2008;52(8):2787-96.
2008: Carol Lackman-Smith; Clay Osterling; Katherine Luckenbaugh; Marie Mankowski; Beth Snyder; Gareth Lewis; Jeremy Paull; Albert Profy; Roger G Ptak; Robert W Buckheit; Karen M Watson; James E Cummins; Brigitte E Sanders-Beer
Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides.
Antimicrobial agents and chemotherapy 2008;52(5):1768-81.
2008: Matthew D Cullen; York-Fong Cheung; Miles D Houslay; Tracy L Hartman; Karen M Watson; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
Bioorganic & medicinal chemistry letters 2008;18(4):1530-3.
2008: Matthew D Cullen; Taradas Sarkar; Ernest Hamel; Tracy L Hartman; Karen M Watson; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
Bioorganic & medicinal chemistry letters 2008;18(2):469-73.
2008: Robert W Buckheit; Tracy L Hartman; Karen M Watson; Sun G Chung; Eui-Hwan Cho
Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.
Antimicrobial agents and chemotherapy 2008;52(1):225-36.
2007: Matthew D Cullen; Bo-Liang Deng; Tracy L Hartman; Karen M Watson; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
Journal of medicinal chemistry 2007;50(20):4854-67.
2007: Marshall L Morningstar; Thomas Roth; David W Farnsworth; Marilyn Kroeger Smith; Karen Watson; Robert W Buckheit; Kalyan Das; Wanyi Zhang; Eddy Arnold; John G Julias; Stephen H Hughes; Christopher J Michejda
Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
Journal of medicinal chemistry 2007;50(17):4003-15.
2007: Takeshi Sakamoto; Matthew D Cullen; Tracy L Hartman; Karen M Watson; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems.
Journal of medicinal chemistry 2007;50(14):3314-21.
2007: Guo Li; Karen Watson; Robert W Buckheit; Yan Zhang
Total synthesis of anibamine, a novel natural product as a chemokine receptor CCR5 antagonist.
Organic letters 2007;9(10):2043-6.
2007: Robert W Buckheit; Tracy L Hartman; Karen M Watson; Ho Seok Kwon; Sun Hwan Lee; Jae Woong Lee; Dong-Wook Kang; Sun G Chung; Eui-Hwan Cho
The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors.
Antiviral chemistry & chemotherapy 2007;18(5):259-75.
2007: José A Fernández-Romero; Mitchell Thorn; Stuart G Turville; Kanani Titchen; Kristin M Sudol; Jifan Li; Todd Miller; Melissa Robbiani; Robin A Maguire; Robert W Buckheit; Tracy L Hartman; David M Phillips
Carrageenan/MIV-150 (PC-815), a combination microbicide.
Sexually transmitted diseases 2007;34(1):9-14.
2006: Bo-Liang Deng; Tracy L Hartman; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Replacement of the metabolically labile methyl esters in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors with isoxazolone, isoxazole, oxazolone, or cyano substituents.
Journal of medicinal chemistry 2006;49(17):5316-23.
2006: Bo-Liang Deng; Matthew D Cullen; Zhigang Zhou; Tracy L Hartman; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Phillip E Fanwick; Mark Cushman
Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings.
Bioorganic & medicinal chemistry 2006;14(7):2366-74.
2006: Brigitte E Beer; Gustavo F Doncel; Fred C Krebs; Robin J Shattock; Patricia S Fletcher; Robert W Buckheit; Karen Watson; Charlene S Dezzutti; James E Cummins; Ena Bromley; Nicola Richardson-Harman; Luke A Pallansch; Carol Lackman-Smith; Clay Osterling; Marie Mankowski; Shendra R Miller; Bradley J Catalone; Patricia A Welsh; Mary K Howett; Brian Wigdahl; Jim A Turpin; Patricia Reichelderfer
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories.
Antimicrobial agents and chemotherapy 2006;50(2):713-23.
2005: Deborah Tien; Roger L Schnaare; Feirong Kang; Gina Cohl; Timothy J McCormick; Thomas R Moench; Gustavo F Doncel; Karen Watson; Robert W Buckheit; Mark G Lewis; Jill Schwartz; Karen Douville; Joseph W Romano
In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials.
AIDS research and human retroviruses 2005;21(10):845-53.
2005: Bo-Liang Deng; Tracy L Hartman; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Phillip E Fanwick; Mark Cushman
Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors.
Journal of medicinal chemistry 2005;48(19):6140-55.
2005: András Horváth; Szilvia Tokés; Tracy Hartman; Karen Watson; Jim A Turpin; Robert W Buckheit; Zsolt Sebestyén; János Szöllosi; Ilona Benko; Thomas J Bardos; Joseph A Dunn; László Fésüs; Ferenc D Tóth; Janos Aradi
Potent inhibition of HIV-1 entry by (s4dU)35.
Virology 2005;334(2):214-23.
2005: Toshiyuki Mori; Barry R O'Keefe; Raymond C Sowder; Scott D Bringans; Roberta S Gardella; Shannon Berg; Pamela Cochran; Jim A Turpin; Robert W Buckheit; James B McMahon; Michael R Boyd
Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.
The Journal of biological chemistry 2005;280(10):9345-53.
2005: Diana M Colleluori; Deborah Tien; Feirong Kang; Tara Pagliei; Ryan Kuss; Timothy McCormick; Karen Watson; Karyn McFadden; Irwin Chaiken; Robert W Buckheit; Joseph W Romano
Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development.
Protein expression and purification 2005;39(2):229-36.
2004: Pratibha Srivastava; Marco L Schito; Rasem J Fattah; Toshiaki Hara; Tracy Hartman; Robert W Buckheit; Jim A Turpin; John K Inman; Ettore Appella
Optimization of unique, uncharged thioesters as inhibitors of HIV replication.
Bioorganic & medicinal chemistry 2004;12(24):6437-50.
2004: Robert W Buckheit
The 17th International Conference on Antiviral Research.
Expert opinion on investigational drugs 2004;13(9):1207-12.
2004: Robert W Buckheit
Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.
Expert opinion on investigational drugs 2004;13(8):933-58.
2004: Tarek Aboul-Fadl; Vijai K Agrawal; Robert W Buckheit; Arthur D Broom
An unusual "senseless" 2',5'-oligoribonucleotide with potent anti-HIV activity.
Nucleosides, nucleotides & nucleic acids 2004;23(3):545-54.
2004: Victor E Buckwold; Richard J H Wilson; Aysegul Nalca; Brigitte B Beer; Thomas G Voss; Jim A Turpin; Robert W Buckheit; Jiayi Wei; Michelle Wenzel-Mathers; Eve M Walton; Robert J Smith; Melanie Pallansch; Priscilla Ward; Jay Wells; Lara Chuvala; Sandra Sloane; Robin L Paulman; Julie Russell; Tracy Hartman; Roger G Ptak
Antiviral activity of hop constituents against a series of DNA and RNA viruses.
Antiviral research 2004;61(1):57-62.
2003: Xin Chen; Lu Yang; Ning Zhang; Jim A Turpin; Robert W Buckheit; Clay Osterling; Joost J Oppenheim; O M Zack Howard
Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy 2003;47(9):2810-6.
2003: Barry R O'Keefe; Donald F Smee; Jim A Turpin; Carrie J Saucedo; Kirk R Gustafson; Toshiyuki Mori; Dennis Blakeslee; Robert W Buckheit; Michael R Boyd
Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin.
Antimicrobial agents and chemotherapy 2003;47(8):2518-25.
2003: Robyn M Hyde; Arthur D Broom; Robert W Buckheit
Antiviral amphipathic oligo- and polyribonucleotides: analogue development and biological studies.
Journal of medicinal chemistry 2003;46(10):1878-85.
2003: Angelica C Giuffre; Joanne Higgins; Robert W Buckheit; Thomas W North
Susceptibilities of simian immunodeficiency virus to protease inhibitors.
Antimicrobial agents and chemotherapy 2003;47(5):1756-9.
2003: Heidi R Bokesch; Barry R O'Keefe; Tawnya C McKee; Lewis K Pannell; Gregory M L Patterson; Roberta S Gardella; Raymond C Sowder; Jim A Turpin; Karen Watson; Robert W Buckheit; Michael R Boyd
A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium.
Biochemistry 2003;42(9):2578-84.
2002: A Geoffrey Skillman; Karl W Maurer; Diana C Roe; Margaret J Stauber; Dolan Eargle; Todd J A Ewing; Angelika Muscate; Elisabeth Davioud; Maxine V Medaglia; Robert J Fisher; Eddy Arnold; Hong Qiang Gao; Robert W Buckheit; Paul L Boyer; Stephen H Hughes; Irwin D Kuntz; George L Kenyon
A novel mechanism for inhibition of HIV-1 reverse transcriptase.
Bioorganic chemistry 2002;30(6):443-58.
2002: Guozhang Xu; Arunachalam Kannan; Tracy L Hartman; Heather Wargo; Karen Watson; Jim A Turpin; Robert W Buckheit; Allison A Johnson; Yves Pommier; Mark Cushman
Synthesis of substituted diarylmethylenepiperidines (DAMPs), a novel class of anti-HIV agents.
Bioorganic & medicinal chemistry 2002;10(8):2807-16.
2002: Guozhang Xu; Tracy L Hartman; Heather Wargo; Jim A Turpin; Robert W Buckheit; Mark Cushman
Synthesis of alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings.
Bioorganic & medicinal chemistry 2002;10(2):283-90.
2002: Robyn M Hyde; Robert W Buckheit; Arthur D Broom
"Senseless" antiviral polyribonucleotides: poly (1-propargylinosinic acid).
Nucleosides, nucleotides & nucleic acids 2002;21(1):45-54.
2001: Guozhang Xu; M Micklatcher; Maximilian Silvestri; Tracy L Hartman; J Burrier; MC Osterling; Heather Wargo; Jim A Turpin; Robert W Buckheit; Mark Cushman
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
Journal of medicinal chemistry 2001;44(24):4092-113.
2001: A Casimiro-Garcia; Erik De Clercq; Christophe Pannecouque; M Witvrouw; TL Loftus; Jim A Turpin; Robert W Buckheit; Phillip E Fanwick; Mark Cushman
Synthesis and anti-HIV activity of cosalane analogues incorporating two dichlorodisalicylmethane pharmacophore fragments.
Bioorganic & medicinal chemistry 2001;9(11):2827-41.
2001: Guozhang Xu; TL Loftus; Heather Wargo; Jim A Turpin; Robert W Buckheit; Mark Cushman
Solid-phase synthesis of the alkenyldiarylmethane (ADAM) series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
The Journal of organic chemistry 2001;66(18):5958-64.
2001: Robert W Buckheit
Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection.
Expert opinion on investigational drugs 2001;10(8):1423-42.
2001: K C Santhosh; G C Paul; Erik De Clercq; Christophe Pannecouque; M Witvrouw; TL Loftus; Jim A Turpin; Robert W Buckheit; Mark Cushman
Correlation of anti-HIV activity with anion spacing in a series of cosalane analogues with extended polycarboxylate pharmacophores.
Journal of medicinal chemistry 2001;44(5):703-14.
2001: Robert W Buckheit; K Watson; V Fliakas-Boltz; Julie Russell; TL Loftus; MC Osterling; Jim A Turpin; Luke A Pallansch; E Lucile White; J W Lee; Sun Hwan Lee; J W Oh; H S Kwon; Sun G Chung; Eui-Hwan Cho
SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2.
Antimicrobial agents and chemotherapy 2001;45(2):393-400.
2000: K C Santhosh; Erik De Clercq; Christophe Pannecouque; M Witvrouw; TL Loftus; Jim A Turpin; Robert W Buckheit; Mark Cushman
Anti-HIV activity of a series of cosalane amino acid conjugates.
Bioorganic & medicinal chemistry letters 2000;10(22):2505-8.
2000: G C Paul; Erik De Clercq; Christophe Pannecouque; M Witvrouw; TL Loftus; Jim A Turpin; Robert W Buckheit; Mark Cushman
Identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates.
Bioorganic & medicinal chemistry letters 2000;10(18):2149-52.
2000: Robert W Buckheit; Julie D Russell; Ze-Qi Xu; Michael T Flavin
Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
Antiviral chemistry & chemotherapy 2000;11(5):321-7.
2000: A Casimiro-Garcia; Erik De Clercq; Christophe Pannecouque; M Witvrouw; TL Stup; Jim A Turpin; Robert W Buckheit; Mark Cushman
Synthesis and anti-HIV activity of cosalane analogues incorporating nitrogen in the linker chain.
Bioorganic & medicinal chemistry 2000;8(1):191-200.
2000: Ze-Qi Xu; E R Kern; Louise Westbrook; L B Allen; Robert W Buckheit; C K Tseng; T Jenta; Michael T Flavin
Plant-derived and semi-synthetic calanolide compounds with in vitro activity against both human immunodeficiency virus type 1 and human cytomegalovirus.
Antiviral chemistry & chemotherapy 2000;11(1):23-9.
1999: A Casimiro-Garcia; M Micklatcher; Jim A Turpin; TL Stup; K Watson; Robert W Buckheit; Mark Cushman
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
Journal of medicinal chemistry 1999;42(23):4861-74.
1999: Robert W Buckheit; E Lucile White; V Fliakas-Boltz; Julie Russell; TL Stup; TL Kinjerski; MC Osterling; A Weigand; JP Bader
Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
Antimicrobial agents and chemotherapy 1999;43(8):1827-34.
1999: Robert W Buckheit; Julie D Russell; Luke A Pallansch; J S Driscoll
Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
Antiviral chemistry & chemotherapy 1999;10(3):115-9.
1999: Yudong Quan; Dimitrios Motakis; Robert W Buckheit; Z Q Xu; M T Flavin; Michael A Parniak; Mark A Wainberg
Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
Antiviral therapy 1999;4(4):203-9.
1999: Robert W Buckheit; Carol Lackman-Smith; M J Snow; S M Halliday; E Lucile White; Larry J Ross; Vijai K Agrawal; Arthur D Broom
PMTI, a broadly active unusual single-stranded polyribonucleotide, inhibits human immunodeficiency virus replication by multiple mechanisms.
Antiviral chemistry & chemotherapy 1999;10(1):23-32.
1998: M G Tutonda; Robert W Buckheit; Vijai K Agrawal; Arthur D Broom
Antiviral oligo- and polyribonucleotides containing selected triazolo[2,3-a]purines.
Journal of medicinal chemistry 1998;41(25):4958-64.
1998: Ze-Qi Xu; Robert W Buckheit; TL Stup; Michael T Flavin; A Khilevich; J D Rizzo; L Lin; DE Zembower
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
Bioorganic & medicinal chemistry letters 1998;8(16):2179-84.
1998: Barry R O'Keefe; T Erim; John A Beutler; John H Cardellina; RJ Gulakowski; BL Krepps; James B McMahon; Raymond C Sowder; Donald G Johnson; Robert W Buckheit; S Halliday; Michael R Boyd
Isolation and characterization of adociavirin, a novel HIV-inhibitory protein from the sponge Adocia sp.
FEBS letters 1998;431(1):85-90.
1998: O M Zack Howard; J J Oppenheim; Melinda G Hollingshead; Joseph M Covey; James C Bigelow; J J McCormack; Robert W Buckheit; DJ Clanton; Jim A Turpin; William G Rice
Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application.
Journal of medicinal chemistry 1998;41(13):2184-93.
1998: Mark Cushman; A Casimiro-Garcia; E Hejchman; JA Ruell; M Huang; CA Schaeffer; K Williamson; William G Rice; Robert W Buckheit
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
Journal of medicinal chemistry 1998;41(12):2076-89.
1998: Jim A Turpin; Robert W Buckheit; D Derse; Melinda G Hollingshead; K Williamson; C Palamone; MC Osterling; S A Hill; L Graham; CA Schaeffer; M Bu; M Huang; Wieslaw Cholody; Christopher J Michejda; William G Rice
Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription.
Antimicrobial agents and chemotherapy 1998;42(3):487-94.
1998: E Lucile White; LM Rose; Paula W Allan; Robert W Buckheit; WM Shannon; John A Secrist
Polyamine pools in HIV-infected cells.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;17(2):101-3.
1997: T Roth; M L Morningstar; Paul L Boyer; S H Hughes; Robert W Buckheit; Christopher J Michejda
Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
Journal of medicinal chemistry 1997;40(26):4199-207.
1997: Marilyn B Kroeger Smith; Christopher J Michejda; Stephen H Hughes; Paul L Boyer; Paul A J Janssen; Koen Andries; Robert W Buckheit; Richard H Smith
Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: implications for the mechanism of polymerase action.
Protein engineering 1997;10(12):1379-83.
1997: Michael R Boyd; Kirk R Gustafson; James B McMahon; Robert H Shoemaker; Barry R O'Keefe; T Mori; RJ Gulakowski; L Wu; M I Rivera; C M Laurencot; Michael J Currens; John H Cardellina; Robert W Buckheit; P L Nara; Lewis K Pannell; Raymond C Sowder; Louis E. Henderson
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.
Antimicrobial agents and chemotherapy 1997;41(7):1521-30.
1997: Robert W Buckheit; Melinda G Hollingshead; S Stinson; V Fliakas-Boltz; Luke A Pallansch; J Roberson; W Decker; C Elder; Suzanne D Borgel; Carrie A Bonomi; R Shores; T Siford; L Malspeis; JP Bader
Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.
AIDS research and human retroviruses 1997;13(9):789-96.
1997: S S Yang; Nagarajan Pattabiraman; Rick Gussio; Luke A Pallansch; Robert W Buckheit; JP Bader
Cross-resistance analysis and molecular modeling of nonnucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus.
Leukemia 1997;11 Suppl 3():89-92.
1997: Robert W Buckheit; M J Snow; V Fliakas-Boltz; TL Kinjerski; Julie D Russell; Luke A Pallansch; W G Brouwer; S S Yang
Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.
Antimicrobial agents and chemotherapy 1997;41(4):831-7.
1997: DE Zembower; S Liao; Michael T Flavin; Ze-Qi Xu; TL Stup; Robert W Buckheit; A Khilevich; A A Mar; A K Sheinkman
Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C).
Journal of medicinal chemistry 1997;40(6):1005-17.
1997: William G Rice; Jim A Turpin; M Huang; DJ Clanton; Robert W Buckheit; David G Covell; Anders Wallqvist; N B McDonnell; R N DeGuzman; Michael F Summers; L Zalkow; JP Bader; R D Haugwitz; Edward A Sausville
Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.
Nature medicine 1997;3(3):341-5.
1997: William G Rice; David C Baker; CA Schaeffer; L Graham; M Bu; S Terpening; DJ Clanton; R Schultz; JP Bader; Robert W Buckheit; L Field; P K Singh; Jim A Turpin
Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins.
Antimicrobial agents and chemotherapy 1997;41(2):419-26.
1997: TL Kinjerski; Robert W Buckheit
The role of genotypic heterogeneity in wild type virus populations on the selection of nonnucleoside reverse transcriptase inhibitor-resistant viruses.
Antiviral research 1997;33(2):109-15.
1997: RJ Gulakowski; James B McMahon; Robert W Buckheit; Kirk R Gustafson; Michael R Boyd
Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV).
Antiviral research 1997;33(2):87-97.
1996: S M Halliday; C Lackman-Smith; JP Bader; William G Rice; D J Clanton; Leon H Zalkow; Robert W Buckheit
Inhibition of human immunodeficiency virus replication by the sulfonated stilbene dye resobene.
Antiviral research 1996;33(1):41-53.
1996: M J Currens; RJ Gulakowski; J M Mariner; R A Moran; Robert W Buckheit; Kirk R Gustafson; James B McMahon; Michael R Boyd
Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1.
The Journal of pharmacology and experimental therapeutics 1996;279(2):645-51.
1996: William G Rice; Jim A Turpin; CA Schaeffer; L Graham; D Clanton; Robert W Buckheit; Daniel W Zaharevitz; Michael F Summers; Anders Wallqvist; David G Covell
Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors.
Journal of medicinal chemistry 1996;39(19):3606-16.
1996: Mark Cushman; W M Golebiewski; L Graham; Jim A Turpin; William G Rice; V Fliakas-Boltz; Robert W Buckheit
Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
Journal of medicinal chemistry 1996;39(16):3217-27.
1996: Jim A Turpin; CA Schaeffer; M Bu; L Graham; Robert W Buckheit; D Clanton; William G Rice
Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor.
Antiviral research 1996;29(2-3):269-77.
1996: James B McMahon; Robert W Buckheit; RJ Gulakowski; M J Currens; D T Vistica; Robert H Shoemaker; S F Stinson; Julie D Russell; JP Bader; V L Narayanan; R J Schultz; W G Brouwer; E E Felauer; Michael R Boyd
Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
The Journal of pharmacology and experimental therapeutics 1996;276(1):298-305.
1995: Robert W Buckheit; T L Kinjerski; V Fliakas-Boltz; Julie D Russell; TL Stup; Luke A Pallansch; W G Brouwer; D C Dao; W A Harrison; R J Schultz
Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.
Antimicrobial agents and chemotherapy 1995;39(12):2718-27.
1995: William G Rice; J G Supko; L Malspeis; Robert W Buckheit; D Clanton; M Bu; L Graham; CA Schaeffer; Jim A Turpin; J Domagala; RD Gogliotti; JP Bader; S M Halliday; Lori V Coren; Raymond C Sowder; Larry O Arthur; Louis E. Henderson
Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS.
Science (New York, N.Y.) 1995;270(5239):1194-7.
1995: Melinda G Hollingshead; J Roberson; W Decker; Robert W Buckheit; C Elder; L Malspeis; J Mayo; Michael R Grever
In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice.
Antiviral research 1995;28(3):265-79.
1995: JO Ojwang; Robert W Buckheit; Yves Pommier; A Mazumder; K De Vreese; José A Esté; D Reymen; Luke A Pallansch; C Lackman-Smith; Tom Wallace
T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy 1995;39(11):2426-35.
1995: S S Yang; V Fliakas-Boltz; JP Bader; Robert W Buckheit
Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Leukemia 1995;9 Suppl 1():S75-85.
1995: Arthur D Broom; V K Agrawal; M G Tutonda; H D Fain; Robert W Buckheit
Unusual single-stranded polyribonucleotides as potent anti-HIV agents.
Journal of medicinal chemistry 1995;38(17):3253-7.
1995: D J Clanton; Robert W Buckheit; S J Terpening; R Kiser; Nicola Mongelli; A L Borgia; R Schultz; V Narayanan; JP Bader; William G Rice
Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV.
Antiviral research 1995;27(4):335-54.
1995: Robert W Buckheit; V Fliakas-Boltz; S Yeagy-Bargo; O Weislow; D L Mayers; Paul L Boyer; Stephen H Hughes; B C Pan; S H Chu; JP Bader
Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
Virology 1995;210(1):186-93.
1995: Robert W Buckheit; V Fliakas-Boltz; W D Decker; J L Roberson; TL Stup; C A Pyle; E Lucile White; James B McMahon; M J Currens; Michael R Boyd
Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups.
Antiviral research 1995;26(2):117-32.
1995: James B McMahon; M J Currens; RJ Gulakowski; Robert W Buckheit; C Lackman-Smith; Yali F Hallock; Michael R Boyd
Michellamine B, a novel plant alkaloid, inhibits human immunodeficiency virus-induced cell killing by at least two distinct mechanisms.
Antimicrobial agents and chemotherapy 1995;39(2):484-8.
1994: Robert W Buckheit; J L Roberson; C Lackman-Smith; Jacqueline R Wyatt; T A Vickers; David J Ecker
Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320).
AIDS research and human retroviruses 1994;10(11):1497-506.
1994: Mark Cushman; W M Golebiewski; James B McMahon; Robert W Buckheit; D J Clanton; O Weislow; R D Haugwitz; J P Bader; L Graham; William G Rice
Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction.
Journal of medicinal chemistry 1994;37(19):3040-50.
1994: Robert W Buckheit; V Fliakas-Boltz; W D Decker; J L Roberson; C A Pyle; E Lucile White; B J Bowdon; James B McMahon; Michael R Boyd; JP Bader
Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors.
Antiviral research 1994;25(1):43-56.
1994: Michael R Boyd; Yali F Hallock; John H Cardellina; K P Manfredi; J W Blunt; James B McMahon; Robert W Buckheit; Gerhard Bringmann; M Schäffer; Gordon M Cragg
Anti-HIV michellamines from Ancistrocladus korupensis.
Journal of medicinal chemistry 1994;37(12):1740-5.
1994: Tawnya C McKee; John H Cardellina; Raffaele Riccio; M V D'Auria; Maria Iorizzi; L Minale; R A Moran; RJ Gulakowski; James B McMahon; Robert W Buckheit
HIV-inhibitory natural products. 11. Comparative studies of sulfated sterols from marine invertebrates.
Journal of medicinal chemistry 1994;37(6):793-7.
1994: Jacqueline R Wyatt; T A Vickers; J L Roberson; Robert W Buckheit; Thomas Klimkait; E DeBaets; P W Davis; B Rayner; J L Imbach; David J Ecker
Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(4):1356-60.
1993: Robert W Buckheit; J Germany-Decker; Melinda G Hollingshead; L B Allen; W M Shannon; P A Janssen; M A Chirigos
Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents.
AIDS research and human retroviruses 1993;9(11):1097-106.
1993: Robert W Buckheit; Melinda G Hollingshead; J Germany-Decker; E Lucile White; James B McMahon; L B Allen; L J Ross; W D Decker; L Westbrook; W M Shannon
Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor.
Antiviral research 1993;21(3):247-65.
1993: Louis S Kucera; N P Iyer; S H Puckett; Robert W Buckheit; L Westbrook; B R Toyer; E Lucile White; J M Germany-Decker; W M Shannon; R C Chen
Activity of triciribine and triciribine-5'-monophosphate against human immunodeficiency virus types 1 and 2.
AIDS research and human retroviruses 1993;9(4):307-14.
1993: James B McMahon; RJ Gulakowski; O S Weislow; R J Schultz; V L Narayanan; D J Clanton; R Pedemonte; F W Wassmundt; Robert W Buckheit; W D Decker
Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Antimicrobial agents and chemotherapy 1993;37(4):754-60.
1992: R N Comber; Robert C Reynolds; J D Friedrich; R A Manguikian; Robert W Buckheit; J W Truss; W M Shannon; John A Secrist
5,5-disubstituted hydantoins: syntheses and anti-HIV activity.
Journal of medicinal chemistry 1992;35(19):3567-72.
1992: Robert W Buckheit; J Germany-Decker; K Qualls-Goodwin; B J Bowdon; W M Shannon
3'-Azido-3'-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(17):8361-5.
1992: Yoel Kashman; Kirk R Gustafson; RW Fuller; John H Cardellina; James B McMahon; M J Currens; Robert W Buckheit; Stephen H Hughes; Gordon M Cragg; Michael R Boyd
The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum.
Journal of medicinal chemistry 1992;35(15):2735-43.
1992: D J Clanton; R A Moran; James B McMahon; O S Weislow; Robert W Buckheit; Melinda G Hollingshead; Vincenzo Ciminale; Barbara K Felber; G N Pavlakis; JP Bader
Sulfonic acid dyes: inhibition of the human immunodeficiency virus and mechanism of action.
Journal of acquired immune deficiency syndromes 1992;5(8):771-81.
1992: Robert W Buckheit; E Lucile White; W M Shannon; A Guerrero; J P Pivel; L Carrasco; J A Leal; M A Chirigos
Significant anti-HIV activity of new modified polyanionic polymers in vitro.
Immunopharmacology and immunotoxicology 1992;14(4):707-21.
1991: E Lucile White; Robert W Buckheit; L J Ross; J M Germany; Koen Andries; R Pauwels; P A Janssen; W M Shannon; M A Chirigos
A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates.
Antiviral research 1991;16(3):257-66.
1991: T Vickers; B F Baker; Phillip Cook; M Zounes; Robert W Buckheit; J Germany; David J Ecker
Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element.
Nucleic acids research 1991;19(12):3359-68.
1991: William B Parker; E Lucile White; Sue C Shaddix; L J Ross; Robert W Buckheit; J M Germany; John A Secrist; R Vince; W M Shannon
Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5'-triphosphates of carbovir, 3'-azido-3'-deoxythymidine, 2',3'-dideoxyguanosine and 3'-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs.
The Journal of biological chemistry 1991;266(3):1754-62.